 |
Deoxycytidine
Research News and Information
Sunday, March 21, 2010
Ceramide metabolism determines glioma cell resistance to chemotherapy.
29 Nov 2009 
Tumor cell resistance to chemotherapy constitutes a major problem in the treatment of malignant tumors. We here investigated the role of ceramide metabolism for the resistance of glioma cells to treatment with the chemotherapeutic drug, gemcitabine. ... Read more...
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
13 Nov 2009 Accumulating evidence suggests that tumors are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. Recently, there have been efforts to explain drug resistance of ... Read more...
30 Oct 2009 This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000 mg/m(2) day 1 & 8 and Irinotecan 100 mg/m(2) day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung ... Read more...
Latest indexed articles for 'Deoxycytidine'
These are the very latest articles for this heading:
- Ceramide metabolism determines glioma cell resistance to chemotherapy. 29 Nov 2009
- CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. 13 Nov 2009
- Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. 30 Oct 2009
- Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. 30 Oct 2009
- Novel agents for the treatment of adenocarcinoma of the pancreas. 29 Sep 2009
- HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment. 29 Sep 2009
- Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. 29 Sep 2009
- Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. 29 Sep 2009
- Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. 29 Sep 2009
- Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts. 29 Sep 2009
- Treatment of disseminated paraganglioma with gemcitabine and docetaxel. 29 Sep 2009
- Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma. 26 Sep 2009
- Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment. 20 Sep 2009
- Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. 19 Sep 2009
- Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. 6 Sep 2009
- Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. 6 Sep 2009
- Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. 5 Sep 2009
- Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? 2 Sep 2009
- Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. 2 Sep 2009
- Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Sep 2009
See a longer list of these articles.
Technical information about 'Deoxycytidine'
Chemical name: Cytidine, 2'-deoxy-
Registry Number: 951-77-9
Descriptor UI: D003841
Alternative terms: Deoxycytidine; CDR; Cytosine Deoxyribonucleoside; Deoxyribonucleoside, Cytosine; Cytosine Deoxyriboside; Deoxyriboside, Cytosine;
Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;
Tree Number: D03.383.742.680.245.500; D13.570.230.329; D13.570.685.245.500;
History Note: 75(73)